🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats to the team 2 InsermU999 for this experimental study in press in Am J Respir Cell Mol Biol "Role of KCNK3 Dysfunction in Dasatinib-associated PAH and Endothelial Cell Dysfunction" Pulmotension Société de Pneumologie de Langue Française (SPLF) FSMR - RespiFIL 🫁 …journals-org.eu1.proxy.openathens.net/doi/metrics/10…

Nous proposons un poste de chef de clinique (CCA) en unité de soins intensifs respiratoires (USIP) de l’hôpital Européen Georges Pompidou (HEGP) (Paris) à partir de Novembre 2024 (fiche ci-jointe). Hôpital européen Georges-Pompidou AP-HP Société de Pneumologie de Langue Française (SPLF) Assistance Publique – Hôpitaux de Paris (AP-HP) AJPO2 - Jeunes Pneumologues AJPO2 - Annonces

Proud to share our recent work published in Chest by the NebuLamB study group #cgodet #grepi Société de Pneumologie de Langue Française (SPLF). CT-scan elementary lesions during ABPA exacerbation and their resolution (or not) at 4mo post Itra+Pds. Important data for future trials. Need CT-scan, IgE and clinics.

Dans cette étude NEJM les patients souffrant d'asthme ou de BPCO non diagnostiqués qui ont reçu un traitement prescrit par un pneumologue ont eu moins recours aux soins de santé pour un problème respiratoire !

Here is the very first basic science paper of our lab. This is a collaborative project with McGill Univ showing an important role of circulating RNA in venous thrombosis. Wonderful team effort!! Francis Couturaud Inserm1304_GETBO UBO - Univ. Brest Inserm Grand Ouest ahajournals.org/doi/10.1161/JA…

Ouverture de l'assemblée générale de notre réseau INNOVTE F-CRIN Quelle meilleure salle que celle ci ? Francis Couturaud Sanchez Olivier Silvy Laporte 💚

Laurent Bertoletti F-CRIN Francis Couturaud Sanchez Olivier Silvy Laporte

Journées FCRIN INNOVTE à l’HEGP, auditorium Guy Meyer. Une journée riche en projets, finalisés et à venir, cliniques et translationnels, nationaux et internationaux. Quel plaisir de poursuivre cette aventure ensemble!

medRxiv New Genomic Discoveries Pave the Way for Research into Predictive #VT recurrence Factors and Innovative Preventive Strategies Gaëlle MUNSCH INNOVTE Francis Couturaud pierre morange Andrew Johnson Florian Thibord Frits Rosendaal among many others

Patients with MPN and splanchnic vein thrombosis who are not receiving anticoagulant therapy seem to have a higher risk of recurrent VTE, bleeding complications and mortality compared to those receiving anticoagulation at 12 months. #ASH24

ASH Late Breaking Abstract: Should patients receive extended duration anticoagulation with reduced or full dose DOAC for the secondary prevention of recurrent VTE - The RENOVE RCT presented by Francis Couturaud Reduced dose DOAC was not non inferior to full dose ((5-year

RENOVE trial: Full dose vs low dose extended anticoagulation in pts requiring long term AC. Conclusions: -similar low rate of recurrence (~2%) in both groups -lower rate of bleeding w low dose -a chance to compare DOAC efficacy (same!) -caution w obesity #ASH24 Francis Couturaud

René Laënnec, médecin breton, né le 17 février (une belle date) 1781 à Quimper et mort de la tuberculose le 13 août 1826 (à 45 ans) à Douarnenez. Parmi ses nombreuses contributions à la médecine, Laënnec a décrit en quelques mois toute la sémiologie pulmonaire 🫁grâce à son

Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial - The Lancet thelancet.com/journals/lance… INNOVTE

The RENOVE trial found that while low-dose DOACs did not meet non-inferiority for preventing recurrent VTE, it showed a better risk-benefit ratio, with less clinically relevant bleeding. Dose reduction may be a good option for many patients! #VTE #DOAC #RENOVE

Postpartum hemorrhage is a significant risk for many women yet the etiology is not well understood. New study from @demoreuil and team shows that women with PPH have a different fibrin network than those who did not. rpthjournal.org/article/S2475-… Brigitte Pan Petesch Brigitte Pan Petesch Francis Couturaud

Prof. Mahé Isabelle presents API-CAT at #ACC2025, published in NEJM Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer. nejm.org/doi/full/10.10…

From Steve Noumegni, one of my brightest PhD student. More about predicting both venous and arterial events after VTE. « Prediction of Recurrent Venous Thromboembolism and Arterial Cardiovascular Events after Discontinuation of Anticoag… pubmed.ncbi.nlm.nih.gov/40203886/

Fantastic scientific meeting on 6th June 2026 in Brest by our research group Inserm1304_GETBO, with brillant interventions, international leaders in VTE from INNOVTE, in Brest. 70 participants. Les Ateliers des Capucins, F-CRIN, CHU Brest, UBO - Univ. Brest , Inserm, CIC1412 inserm.

🩸 New insights from the RENOVE trial (extended duration anticoagulation) at #ISTH2025: 📉 Reduced-dose DOAC is non-inferior in patients with BMI <30, with less bleeding risk. ⚠️ But in patients with BMI ≥30, reduced-dose may be inferior for bleeding and recurrent VTE. ➡️